Eosinophilia is a uniquely specific phenomenon regulated by interleukin-5 (IL-5). suggesting specific control for IL-5 gene expression. Using a transient-transfection reporter assay and DNA mobility-shift experiments in EL4 mouse lymphoma cells, reporter expression and binding of transcription factors t o the conserved lymphokine element 0 (CLEO) in the mouse (mlL-5) promoter was investigated. Activation of the IL-5 promoter required costimulation of T cells with phorbol ester (phorbol 12-myristate 13-acetate IPMAI) and cyclic adenosine 3',5'-monophosphate (CAMP), but was blocked by the immunosuppressive drug, cyclosporin A (CsA). Binding t o CLEO was induced under conditions optimal for IL-5 transcription but was not blocked by &A. CD28-induced signals could partly substitute for CAMP. However, the effects of CAMP, but not of CD28, were sensitive t o the CAMP-dependent protein kinase inhibitor, H89, suggesting that CD28 does not involve a CAMP mechanism. It therefore appears that IL-5 expression can be induced by at least two distinct stimulatory pathways. Although CLEO contains sequences similar t o AP-1 and NF-AT, only the AP-1 moiety of NTERLEUKIN-5 (IL-5) is a lymphokine produced pri-I marily by activated T cells, and is involved in the production, activation, and differentiation of eosinophil^.'.^ Eosinophils are the major cause of tissue damage resulting in the symptoms of asthma and other allergic diseases? Asthma is also often associated with IgE-mediated degranulation of mast cells, implicating the involvement of IL-4, a cytokine that plays an important role in the induction of IgE.5 Eosinophilia is a biologically specific phenomenon that can occur in the absence of increases in other blood leukocytes and in the absence of IgE.
I marily by activated T cells, and is involved in the production, activation, and differentiation of eosinophil^.'.^ Eosinophils are the major cause of tissue damage resulting in the symptoms of asthma and other allergic diseases? Asthma is also often associated with IgE-mediated degranulation of mast cells, implicating the involvement of IL-4, a cytokine that plays an important role in the induction of IgE.5 Eosinophilia is a biologically specific phenomenon that can occur in the absence of increases in other blood leukocytes and in the absence of IgE.
Studies with T-cell clones in vitro, particularly the Th2 clones, indicate that IL-4 and IL-5 are often coexpressed. 6 However, anti-CD3 induces the expression of IL-4, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA in mouse T cells, whereas treatment with IL-2 stimulates IL-5 "A expression but does not induce expression of detectable amounts of IL-4 or GM-CSF mess e n g e r~.~ T-cell hybrids expressing IL-5 and no other lymphokine have been produced.8 Some subclones of the mouse EL4 lymphoma cell line produce a broad range of cytokines, including IL-2, IL-4, and IL-5, whereas others express IL-2 but not IL-5. These observations, together with the fact that eosinophilia can occur without increased expression of lymphokines other than 1L-5,4 suggest that a unique control mechanism for this lymphokine must exist.
Expression of most cytokine genes appears to be predominantly regulated at the level of initiation of transcripti~n.~~'~ Analysis of the mouse IL-5 (mIL-5) promoter showed that a sequence spanning the region -41 to -55 upstream of the RNA initiation site is also present in the 5' upstream region of IL-3, IL-4, and GM-CSF genes." This conserved lymphokine element (CLEO) was found to be essential for GM-CSF" and IL-5I3 promoter activity, and has been shown to mediate the induction signal during activation of the GM-CSF gene."
Activation of T cells requires the interaction of the T-cell
the CLEO element could be demonstrated t o have inducible binding. Experiments with antisera t o the AP-1 family of transcription factors indicated that c-fos and JunB bind t o the IL-5 CLEO in activated lymphoma cells. The role of the NF-AT-like element was less clear. A constitutively expressed protein showed a weak band that was inhibited by mlL-2 NF-AT competitor sequences. However, this protein did not react with an anti-NF-ATp antiserum. On the other hand, transcription was partially inhibited by an oligonucleotide containing the intact NF-AT-like element from CLEO, suggesting that the element is important for optimal transcription, but the nature of the protein binding t o it remains unknown. The fact that these factors are induced in a subclone of EL4 that does not express IL-5 and bind t o a number of other cytokine gene promoters suggests that although binding t o CLEO appears t o be necessary for IL-5 transcription, other factors must control the specific expression of the gene. 0 1996 by The American Society of Hematology.
receptor (TCR) complex with antigen in association with the major histocompatibility complex, which leads to an increase in intracellular calcium concentration and activation of protein kinase C (PKC).I4 These processes can be bypassed by stimulating T cells with phorbol 12-myristate 13-acetate (PMA) and ionomycin. However, stimulation of the TCR alone is insufficient to fully activate most T cells, and a second signal provided by antigen-presenting cells (APC) is also req~ired.'~ This costimulatory signal can be generated by the CD28 ligand.I6 Efficient production of IL-5 requires activation of both the TCR and a second signaling pathway. Anti-CD28 monoclonal antibody (MoAb)I7.l8 or cyclic adenosine 3',5'-monophosphate CAMP)'^.'' in combination with PMA were shown to be necessary for optimal induction of IL-5 synthesis. AP-1 is a transcription factor rapidly induced in activated T cells, and it is involved in the activation of many cytokine genes." A sequence related to the consensus AP-1 binding has been identified in the CLEO element of the mILsite22.2' 5 promoter," suggesting that AP-1 -related factors may regulate expression of this gene during T-cell activation. In activated murine T cells, c-Fos and JunB are the factors most commonly present in inducible AP-1 complexes.24 AP-1 DNA-binding activity is induced by PKC activators, notably phorbol esters." However, a recent study has shown that AP-1 transcriptional activity requires PKC activation and Ca2' increase, as well as a costimulatory signal that can be provided by the interaction of CD28 with its ligand expressed on APC.'$ In the present study, we developed a transient-transfection assay for measuring the activity of mIL-5-luciferase reporter gene constructs in EL4 mouse lymphoma cells. Reporter expression was compared with the binding of transcription factors to CLEO by DNA mobility-shift experiments.
MATERIALS AND METHODS

Plasmids.
To generate the mIL-5-luciferase construct (Fig 1 ) , the following strategy was used. The XbaI (-313)-KpnI (+2589) fragment of the mIL-5 genomic sequencezs was isolated and subcloned into M13. A Sal1 restriction site was introduced by sitedirected mutagenesis into the IL-5 gene immediately downstream of the cap site. This Sun site was used to insert a cDNA, with Safl linkers, encoding the luciferase gene. The XbaIlKpnl-luciferase fragment was then subcloned into pUC19 (plasmid pUC-IL5XK-Luc). The plasmid mlL5-HB-Luc was made by inserting the Hind111 (-3861)-RamHI (+5612) mIL5 genomic fragment between the corresponding sites of the vector pPolyIII-12' (intermediate construct pIlI-ILS-HB). The luciferase gene was introduced by replacing the Hpal (-241)-KpnI (+2529) fragment of pIII-IL5-HB with the corresponding fragment from pUC-IL5XK-Luc.
The IL-2-luciferase construct was provided by T.M. william^.^' It contains 600 bp from the human IL-2 promoter linked to the luciferase reporter gene. The construct pEF-Bos-Luc was obtained by inserting the luciferase gene downstream of the EF-la promoter in the eukaryotic expression vector ~EF-BOS.~" EL4 cells, a mouse thymoma cell line,?' were maintained in RPMI 1640 medium supplemented with I mmol/L sodium pyruvate, 2 mmol/L glutamine, 100 UlmL penicillin, 100 pglmL streptomycin, and 10% fetal calf serum. For T-cell activation, PMA (Sigma, St Louis, MO) and CAMP (Bt,cAMP; Sigma) were used at concentrations of 20 ng/mL and 1 mmol/L, respectively. The mouse anti-CD28 (37.51) MoAb was obtained from Pharmingen (San Diego, CA) and was used at a final Cell transfection and luciferase assay. concentration of 1 pg/mL. Cyclosporin A (CsA) was purchased from Sandoz (Basel, Switzerland). The CAMP-dependent protein kinase inhibitor, H89, was obtained from Calbiochem Inc (Luceme, Switerzland) and used at a concentration of 5 pmollL.
For transfection studies, 20 pg DNA was electroporated at 960 p F and 270 V into 10' EL4 cells in 400 pL RPMI medium. After electroporation, the cells were diluted into 15 mL medium and incubated for 24 hours at 37°C. The cells were then procured and placed in a 24-well plate at a density of 10' cellslmL (1 mWwell) and incubated for 6 to 48 hours in the presence of various agents.
The cells from each independent well were finally obtained and then resuspended in 100 pL lysis buffer (50 mmol/L Tris-HCI, pH 7.8, 15 mmol/L MgS04, 33.3 mmollL dithiothreitol, 0.1 mmol/L EDTA, 250 pmol/L LiCoA [Sigma], 500 pmol/L Na-luciferin [Molecular Probes], and 0.5% Triton X-100). and luciferase activity was measured in a Microbeta 1516 luminometer (Wallac, Turku, Finland). The background obtained from the lysis buffer was subtracted from each sample. Experimental values are expressed relative to the activity found in extracts from unstimulated cells (equal to background). The absolute values at stimulation vary between 10 and 500 relative luciferase units. Results are the mean of three independent experiments with duplicates. Error bars represent standard deviations.
Supematants of the cells electroporated with the various luciferase constructs were tested for IL-2 and IL-5 production. IL-2 content was measured in relative units using 'Hthymidine uptake in CTLL cells. 1L-5 content was measured using Baf-IL-5 cells. The mIL-3-dependent cell line was stably transfected with the human IL-5 receptor a-chain (J. Van der Heyden, unpublished, 1993). The cells were then stably transfected with the luciferase reporter gene under the control of the HCMV promoter. Cell proliferation was determined by measuring luciferase activity (C.J. Sanderson, unpublished) .
EL4 nuclear extracts were obtained from a small number of cells (2.5 X IO6) using the method described by Schreiber et al' " with the following modifications. Leupeptin and aprotinin (1 pglmL, respectively) were added to the reaction buffers just before lysis. Standard binding reactions contained 1 to 2 pg nuclear proteins (unless otherwise specified), 60 mmol/L KCI, 8 mmol/L MgCI2, 12 m m o m HEPES, pH 7.9, 12% glycerol, 0.1 mmol/L EDTA, 1 mmol/L dithiothreitol, 3 pg poly(d1-dC), and 25 fmol end-labeled oligonucleotide probe. Probe preparation, protein-DNA binding reactions, competitive binding studies, and analysis by polyacrylamide gel electrophoresis were performed as described by Karlen and Beard."
DNA supershift experiments were performed using the method described by Jain et al." Antisera against c-Fos? the Jun family (cJunlAP-I(D)), c-Jun (c-JunlAP-l(N)), JunB (N-17). JunD (329). ATF-IKREB (25C106). and ATF-2 (C19) were obtained from Santa Cruz Biotechnology. Purified Fos MoAb against the M peptide and NF-AT antisera were kindly provided by J. Jain (Dana-Farber Cancer Institute, Boston, MA). Before being used in a supershift reaction, the antibodies were tested in a binding reaction to eliminate the possibility that nonspecific interaction with the probe might inhibit protein binding. A low level of reactivity was observed with c-Jun and JunD, but with none of the others.
The oligonucleotides used for competition and DNA mobilityshift experiments were the following. The CLEO element encompassing the region between positions -37 and -58 in the mIL-5 promoter contained the sequence 5'-GCAATTATTCA-TTT%CT-CAGAG-3'. The oligonucleotides, mut 1 (5'GCAACTCAACAT-TTCCTCAGAG-3') and mut2 (5'-WAATTA'ITCATGGAm& IGAG-3') were prepared with mutations destroying i n x C L E O binding site the AP-I -and NF-AT-like moieties, respectively. The The same DNA fragment (HindIII (-3861)-BamHI (+5612) was therefore used as a starting point for studying the expression of IL-5 in vitro (Fig 1) . The luciferase reporter gene was inserted into the IL-5 genomic sequence immediately downstream of the cap site without deleting any of the genomic sequences (Fig 1) . This construct (mIL-5-HB-Luc) was electroporated into two subclones of mouse EL4 lymphoma cells that differ in IL-5 expression: EL4-23 and EL4-16 cells express, respectively, high levels or very low levels of IL-5. Twenty-four hours after electroporation, the cells were stimulated with phorbol 12-myristate 13-acetate (PMA), which is sufficient to stimulate expression of most of the cytokine genes in EL4 cells,'' CAMP, or combinations of the two. Expression of the reporter gene was monitored at different times.
Stimulation for 12 hours in the presence of PMA and cAMP was optimal for expression from the IL-5 promoter in EL4-23 cells (Fig 2A) . However, PMA and cAMP individ-T 125 1 -ually were shown to have almost no effect on promoter activity. In ELA-16, very low IL-5 promoter activity was observed (Fig 2A) and only low levels of IL-5 were measured (Fig 2B) . Both EL4 subclones produce IL-2 (Fig 2D) , and 48 hours after stimulation, high expression from the IL-2 promoter was observed in both subclones (Fig 2C) . This stimulation was almost totally inhibited when cAMP was used in combination with PMA. In contrast, stimulation of the IL-2 promoter in EL4-23 cells with PMA alone was almost undetectable 6 hours after addition of the activator, but promoter activity could be observed in the presence of both PMA and CAMP. Interestingly, cAMP has been shown to have a delayed inhibitory effect on several regulatory factors, particularly NF-kB, involved in IL-2 transcription.36 This observation may explain the transition shown by cAMP from an early activator to a late inhibitor of IL-2 expression.
cAMP has been reported to regulate IL-5 gene expression by acting synergistically with PMA.I9 Our experiments show that a combination of both activators caused a marked increase in the production of IL-5 in EL4-23 cells, although incubation for 48 hours with PMA alone was sufficient to stimulate some IL-5 production (Fig 2B) . Interestingly, incubation with PMA alone led to detectable IL-5 promoter activity only 24 hours after the beginning of treatment (Fig 2A) . In contrast, expression from the IL-5 promoter was considerably increased 12 hours after addition of both PMA and CAMP, but after 48 hours promoter activity had decreased to the level obtained with PMA alone. These observations confirm that cAMP in combination with PMA is required for early promoter activity in EL4 cells.
A PMNcAMP-inducible complex binds to the mIL-5 CLEO element. In the mIL-5 gene, the region extending from -41
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From to -55 has only a single base difference with the GM-CSF CLEO sequence." This sequence was found to be essential for IL-5 promoter activity." In GM-CSF. binding to the CLEO element is induced in activated T cells and the CLEO sequence is recognized by factors related to AP-I and NF-AT." DNA mobility-shift experiments with extracts from EL4 cells were performed to identify inducible factors binding to that region. A 22-bp oligonucleotide, which covers the mIL-5 promoter region from position -58 to -37 and includes the CLEO-like sequence, was used in the assay. Strong binding to the CLEO sequence was observed after stimulation of the cells with a combination of PMA and cAMP (Fig 3) . although lower levels of binding were also obtained with extracts from cells treated with only one of the activators. A slight difference in the mobility of the complex detected with PMA alone versus cAMP was observed. This may be due to the different phosphorylation pattern induced by PKC and PKA, two protein kinases activated by PMA and CAMP, re~pectively.~' Interestingly, binding was observed with extracts of both EL4-23 and EL4 - tracts were used. two additional bands could be seen with both induced and noninduced extracts (Fig 4B) . Sequence analysis of the CLEO element showed that the 5' moiety of the site is an AP-I binding sequence, whereas the 3' portion closely resembles an NF-AT binding site ( Fig  Mutations destroying either the AP-I binding site ( Fig  4A, mutl) or the NF-AT-like binding site (mut2) were introduced into the mIL-5 CLEO element. These mutated oligonucleotides were used as competitor sequences in the DNA mobility-shift assay. Binding of the PMAkAMP-inducible complex to the CLEO site (Fig 4B) was not affected by a 20-fold molar excess of mutl binding sequence, whereas a similar excess of unlabeled CLEO oligonucleotide strongly inhibited formation of the complex. Binding of the inducible complex was similarly strongly inhibited when an excess of mut2 oligonucleotide was added to the reaction. Added mIL-2/AP-1 binding sequences acted as competitors interfering with formation of the inducible complex. In contrast, addition of efs oligonucleotide was ineffective. These data suggest that proteins of the AP-I family were interacting with the CLEO binding site.
For The competition studies performed with the mut2 oligonucleotide sequence suggested that the 3' half of the mIL-5 CLEO site might not be required for binding of the inducible complex. However, in the GM-CSF gene the 3' part is involved in NF-AT To investigate whether NF-AT was present in the PMNcAMP-inducible complex bound to the mIL-5 promoter, an unlabeled oligonucleotide probe containing the high-affinity mIL-2 NF-AT binding site was used for competition studies. This oligonucleotide did not compete for binding of the inducible complex, but strongly inhibited formation of the faster-migrating complex ( Fig  4B) . Formation of this lower complex was partially affected when an excess of mutl competing sequence was added to the reaction. Addition of the mIL-2lAP-1 oligonucleotide was, in contrast, ineffective. These data indicate that the weak fast-migrating complex bound to CLEO could be a constitutively expressed NF-AT.
Interestingly, binding of the upper complex (Fig 4B) was not affected by excess amounts of AP-1 or ets sequence. Only oligonucleotides containing an intact CLEOlAP-1 site (the intact CLEO and the mut2 sequence) inhibited formation of the upper band. Addition of mIL-2 NF-AT or mutl competitors slightly interfered with binding. These results suggest that NF-AT may associate with a third, non-AP-1-related factor to form a complex that requires an intact CLEO site for binding.
CLEO is an important mediator of IL-5 promoter activity. In the mIL-5 gene, the sequence covering the CLEO motif was found to be essential for IL-5 promoter a~tivity.'~ To examine the potential biologic significance of the mutl and mut2 mutations in IL-5 transcription, EL4-23 cells were electroporated with the mIL-5-Luc construct in the presence of increasing amounts of double-stranded competitor oligonucleotide (Fig 5) . IL-5 promoter activity was strongly affected when CLEO wild-type competing sequences were added to the reaction. Transcription was similarly affected with addition of the mut2 oligonucleotide, which has the potential to compete for AP-1 binding. In the presence of mut 1 competing sequences, which can compete for NF-AT binding in the CLEO site, a significant decrease in promoter activity was observed but some levels of transcriptional activity could still be measured. However, addition of the CK2 oligonucleotide, a mIL-5 promoter sequence unrelated to CLEO, was ineffective. These data indicate that the AP-1 part of the CLEO element is indispensable for IL-5 promoter activity.
They also suggest that binding of an NF-AT-like complex is required for maximal transcription.
The inducible complex binding to CLEO contains c-Fos and JunB. Since the CLEO binding site appears to contain a functional AP-1 motif, we performed experiments to determine whether members of the Fos and Jun families were present in the CLEO DNA binding complex. For these experiments, a variety of antibodies raised against Fos and Jun proteins were used in DNA mobility supershift experiments (Fig 6) . Antisera that recognized all known Jun family members were shown to supershift the CLEO complex and to almost completely inhibit its binding (Fig 6) . Antisera that specifically bind to JunB also supershifted the CLEO complex. In contrast, neither JunD-nor c-Jun-specific antisera had any detectable effect on the CLEO bandshift. Since JunB appears not to form homodimers:' we searched for the presence of members of the Fos family in the inducible complex. An antiserum that broadly reacts with several members of the Fos family3* was found to interfere with formation of the CLEO complex (Fig 6) . Moreover, addition to the binding reaction of an antibody specific for c-Fos clearly induced supershifting of part of the CLEO band.
Jun and Fos proteins can also heterodimerize with members of the ATFlCREB f a~n i l y .~~.~~ Since both PMA and CAMP in combination were shown to be necessary for optimal stimulation of CLEO binding (Fig 3) , we were interested in knowing whether members of the ATFlCREB family were also present in the complex. Antisera that recognize either ATF-1lCREB or ATF-2 factors had no effect on the CLEO binding complex (Fig 6) . Together, these results suggested that a c-FoslJunB heterodimer might preferentially bind to the mIL-5 CLEO element in cells stimulated with PMA and CAMP.
Finally, antibodies raised against NF-ATp4' were used in the DNA mobility supershift assay. Although the antibody recognized a complex bound to the mIL-2 NF-AT site, it did not supershift the NF-AT-like complex bound to CLEO (Fig 6B, and data not shown) . Thus, we were unable to obtain direct evidence that the complex contained an NF-AT protein.
The costimulatory signal required for CLEO binding and IL-5 transcription can be provided by CD28. In addition to the signals delivered by the TCR, T-cell activation requires a second, antigen-independent costimulatory signal that can be generated by activating the CD28 pathway.16 CD28 was reported to increase the stability of several cytokine ~R N A s ?~ and was also observed to participate directly in the transcription of some interleukin IL-5 expres- (Fig 7A) . Alone, each stimulus resulted in little (PMA) or no (CD28) activation. However, the combination of PMA and anti-CD28 was less efficient than the combination of PMA and CAMP. In the presence of PMA and anti-CD28, promoter activity was low during the first 12 hours of stimulation, and readily detectable activity was only measured 24 hours from the beginning of treatment (Fig 7B) . Since the luciferase gene is linked to the IL-5 genomic sequence, it is possible that the effect observed with anti-CD28 may result from stabilization of the reporter gene mRNA through posttranscriptional mechanisms. However, 
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CD28 in combination with PMA was still able to activate a construct containing the luciferase gene under the unique control of the mIL-5 promoter, indicating direct participation of CD28 in transcription of the IL-5 gene (data not shown).
Binding to the CLEO element was observed with extracts from cells treated with both activators (Fig 7C) . PMA stimulation alone was sufficient to induce binding, although the level of binding was enhanced by addition of anti-CD28 MoAbs. In contrast. a low level of binding to the CLEO element was observed with extracts from cells stimulated with anti-CD28 alone. Both c-Fos and JiirtB were present in the complex (data not shown). In addition, detection of the constitutive faster-migrating complex was enhanced when anti-CD28 was used as a costimulant (Fig 7C and  8B) . The nature of this NF-AT-like complex was discussed earlier. Interestingly, the kinetics in the formation of the CLEO complex were different depending on the type of inducer. When cells were stimulated with PMA plus CAMP, binding to the CLEO oligonucleotide was rapidly induced (Fig 7D) . Maximal induction was reached after 6 hours of stimulation, and thereafter the efficiency of binding started to decrease, and decreased to less than 20% of the maximum (as determined by densitometry scanning of the autoradiogram). However, in cells treated with PMA and anti-CD28, slow induction of CLEO binding was observed. Maximal induction was obtained after 8 hours, and no decrease in binding efficiency could be observed for at least 12 hours from the beginning of treatment. These results confirmed that CD28 or cAMP in combination with PMA are involved in IL-5 production.
It has been suggested that the signaling pathways used by CD28 are independent of changes in cAMP concentrations.'' To address the possibility that IL-5 transcription and CLEO binding may be induced by independent activation pathways, we analyzed the effects of H89, a specific inhibitor of CAMPdependent protein kinases.''6 IL-5 promoter activity was strongly reduced by H89 at induction with PMA plus cAMP (Fig 8A) . However, expression from the IL-5 promoter was not affected by H89 in cells treated with PMA alone or PMA in combination with anti-CD28. Similarly, binding to the CLEO element was significantly reduced by H89 in PMAtreated cells costimulated with CAMP, whereas no effect of H89 on binding was observed when cells were stimulated with PMA either alone or in combination with antLCD28 ( Fig 8B) . This indicates that IL-5 expression can be induced by alternative stimulatory pathways.
CsA is an immunosuppressive drug that blocks calcium-dependent signaling via the TCR, by inhibiting the Ca"/calmodulin-dependent phosphatase, ~alcineurin.~' CsA has been shown to dosedependently suppress the production of IL-5 in vitro, and it has been suggested that the block could be at the transcriptional
To investigate whether CsA could affect transcription from the IL-5 promoter, EL4-23 cells were electroporated with the mIL-5-HB-Luc construct or the control vector pEF-Bos-Luc in the presence of PMA and cAMP and increasing concentrations of CsA. The cell pellets were tested for luciferase activity (Fig 9A) and the supernatants for IL-5 production ( Fig 9B) . As expected, CsA completely inhibited PMNcAMP-induced production of IL-5 by EL4-23 cells electroporated with both constructs (Fig 9B) . Moreover, IL-5 promoter activity was strongly reduced in the presence of increasing concentrations of CsA, whereas transcription from the control vector pEF-Bos-Luc was not affected (Fig 9A) . Nuclear extracts from CsA-treated cells were tested in a mobility-shift assay with the mIL-5 CLEO oligonucleotide. No effect on transcription factor binding to CLEO was observed for CsA over the same concentration range (data not shown).
IL-5 transcription is inhibited by
DISCUSSION
Although it has been shown that IL-5 production requires activation of both the TCR and a second signaling path~a y , '~.~~-' * little is known about the mechanisms that regulate expression of the IL-5 gene in activated T cells. Herein, we show that activation of the IL-5 gene in EL4 mouse lymphoma cells can be triggered by at least two inducers that act synergistically with phorbol esters. Whereas PMA stimulates only low-level IL-5 promoter activity, its effect is enhanced by cAMP or anti-CD28 MoAb, which by themselves have no effect on IL-5 promoter activity (Fig 2A) . These two inducers together with PMA lead to the formation of an AP-1 complex that binds to the CLEO element of the mIL-5 promoter (Figs 4,5, and 7A) . Synergy between PMA, CAMP, and calcium ionophore in the activation of the IL-5 gene was also recently reported." AP-1 is critically involved in the activation of many cytokine gene^^'.'^ either by binding directly to the promote??
or as a component of an NF-AT c o m p l e~. '~~~~~~' The mIL-5 CLEO element is composed of two overlapping sites showing high homologies with an AP-I and an NF-AT binding sequence (Fig 1) . We observed that only proteins of the Fos/ Jun family (c-Fos and JunB, respectively) were present in the CLEO complex, together with a weak complex resembling NF-AT. Our data using a competition/transcription assay suggested that binding of AP-I to the CLEO element was crucial for IL-5 promoter activity in activated T cells. In contrast, binding of an NF-AT-like factor was not decisive, and only partial inhibition of transcription occurred. Inducible binding of AP-I to CLEO, together with a weak NF-AT complex, has recently been reported for activation of the GM-CSF gene.3* In this latter report, the investigators used purified AP-1 and NF-AT factors to show that both proteins could bind independently to the GM-CSF CLEO sequence. In addition, AP-I and NF-AT could combine and form a third complex of higher molecular weight. In our system, independent binding of AP-I and an NF-AT-like factor to the mIL-5 CLEO element was also observed. In addition, a third complex, which might be related to NF-AT, was associated with the CLEO probe. However, formation of this complex did not require the presence of AP-I factors. Masuda et allz reported a similar observation for the formation of an NF-AT-related complex on the human GM-CSF CLEO. Together, these results suggest that NF-AT may associate with a third factor for binding to the CLEO sequence. Activation of the IL-5 promoter and binding to the mIL-5 CLEO element were induced by treating EL4-23 cells with either cAMP or anti-CD28 together with PMA (Figs 2 and  6 ). However, although cAMP markedly enhances the expression of IL-5, it has an inhibitory effect on IL-2, IL-3, IL-10, and GM-CSF'9.'h.s6 and no effect on IL-4.'7 On the other end, the influence of CD28 costimulation on cytokine production (including IL-4 and IL-5) has been shown to be mainly regulated via an increase in the production of IL-2." These observations strongly suggest that IL-5 expression may be controlled by at least two independent costimulatory pathways. Our results using the CAMP-dependent protein kinase inhibitor, H89, support this hypothesis. H89 was shown to have no effect on CD28-mediated activation of IL-5 promoter activity, but it significantly reduced the stimulatory effect of cAMP (Fig 7) . The fact that IL-5 expression can be induced by alternative pathways is of particular interest in the context of asthma. The classic association between eosinophilia and high IgE levels and the coexpression of these two cytokines in some T-cell clones from allergic pa- antib~dy.~' In contrast, cAMPL9 and histamine" have been shown to increase the production of IL-5 in activated T cells, whereas IL-4 production was not affected. The induction by histamine was mediated via histamine H2 receptors which are known to activate CAMP-dependent protein kinase signaling pathway^.'^ How these observations relate to stimulation of the TCR by antigen is not yet clear, but it indicates that the two genes are not coordinately regulated.
Since binding of AP-1 to the mIL-5 CLEO element was observed in cells treated with either PMA/cAMP or PMA/ CD28, it seems likely that AP-1 is essential in modulating the induction signals. One component of the complex binding the AP-I/CLEO element was JunB. Unlike other Jun proteins, JunB can be activated by PKC and CAMP-dependent protein kinase Therefore, JunB might be one of the points of convergence of induction signals involved in activation of the IL-5 gene. Recently, JNK has been shown to be an essential player in the integration of signals leading to T-cell activation.62 A well-characterized effect of JNK is to potentiate AP-1 Hence, JNK is an attractive candidate mediator for JunB activation. On the other hand, binding of AP-1 to the CLEO element was observed in two subclones of EL4 that differ in IL-5 expression (Fig 3) . This indicates that additional control elements are necessaq for regulating IL-5 transcription. A CTF/NF-1 site in the upstream enhancer or the IL-5 regulatory region was shown to be required for inducible expression,6s and a palindromic sequence at position -481 in the human IL-5 promoter was involved in the regulation of the gemh6 Involvement of Oct factors" and GATA4 at two sites immediately adjacent to the CLEO region was also documented.
Transcription of most cytokine genes in activated T cells is blocked by the immunosuppressive drug, CSA.'~ However, conflicting results regarding the effect of CsA on IL-5 expression have been reported. CsA inhibits transcription of IL-5 in human peripheral blood mononuclear ~e l l s , ' "~~~~~' but it appears to have no effect in mouse lymphoma ~e l l s .~~'~~~* However, in our system, treatment with CsA blocked transcription of the IL-5 gene in mouse EL4-23 cells (Fig 9A) . The inhibition was not due to a cytotoxic effect of the drug, because transcription from a control vector was not affected. The CsA-mediated block in cytokine expression is partially explained by the inhibition of both DNA binding and transcriptional activity of the T-cell regulatory factor. NFWe observed that binding to the CLEO region of the mIL-5 promoter is not affected by CsA (data not shown). However, in EL4-23 cells, a high level of NF-AT binding to the mIL-2 NF-AT element occurs in unstimulated cells, suggesting that calcineurin is constitutively activated in those cells (S. Karlen, unpublished data). Binding of the weak NF-AT-like complex to the mIL-5 CLEO region may therefore still be possible in CsA-treated cells, although its transcriptional activity would be affected. The recent characterization AT. 41 .54 of a transcriptionally active CsA-sensitive NF-AT binding site upstream of the CLEO element may also explain the inhibitory effect of CsA on the IL-5 promoter observed in our ~y s t e m .~~. '~ Alternatively, the regulatory activity of factors not yet identified might be affected by the drug.
Our results make it clear that the CLEO/AP-1 site has an important role in transcriptional control by responding to at least two distinct induction signals. Such a dual-activation system provides a basis to understand the particular pattern of expression shown by IL-5 in allergic disorders.
